A first test of the pill AO-252 in people with advanced solid tumors, including tumors that spread to the brain
Official title: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a new pill called AO-252 to see if it is safe and what dose is best.
Read our full plain-language summary
What the trial team says
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Key facts
- Registry number
- NCT06136884
- Stage of testing
- Phase 1
- Conditions studied
- Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Where it is running
This trial lists 6 sites.
-
Michigan
- Karmanos Cancer Institute (Detroit)
-
Oklahoma
- Oklahoma Univeristy (Oklahoma City)
-
South Carolina
- Hollings Cancer Center - MUSC (Charleston)
-
Texas
- Mary Crowley Cancer Research (Dallas)
- The University of Texas M.D. Anderson Cancer Center (Houston)
-
Virginia
- Next Oncology -Virginia (Fairfax)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.